Company Overview of EnGeneIC Ltd.
EnGeneIC Ltd., a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.
2/25 Sirius Road
Lane Cove West, NSW 2066
Founded in 2000
Key Executives for EnGeneIC Ltd.
Co-Managing Director and Director
Founder, Co-Managing Director and Director
Compensation as of Fiscal Year 2015.
EnGeneIC Ltd. Key Developments
EnGeneIC Ltd. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 04:30 PM
Nov 11 15
EnGeneIC Ltd. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 04:30 PM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Jennifer A. MacDiarmid, Founder, Co-Managing Director and Director.
EnGeneIC Ltd. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 04:00 PM
Sep 3 15
EnGeneIC Ltd. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 04:00 PM. Venue: Parc 55 Hotel, San Francisco, California, United States.
EnGeneIC Ltd. Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors
Aug 19 15
EnGeneIC Ltd. announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia. The Phase 1 Tailored-EDV trial is an open-label feasibility study of a single delivery agent (EGFR)-EDVs packaged with the clinician's chosen therapy in subjects with advanced solid tumors who have no further curative treatment options. Eligible patients with a variety of intractable tumor indications, including triple-negative breast cancer, non-small cell lung cancer and metastatic colorectal cancer, will be dosed intravenously, receiving a combination of (EGFR)-EDVs, chemotherapy and functional nucleic acids, such as siRNA, which may address issues of chemotherapy resistance. The therapeutic payload for each patient will be specifically chosen for his or her individual disease. The first patient dosed is suffering from advanced Adrenal Cell Carcinoma (ACC) and received a siRNA that blocks cell division.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 12, 2015
December 12, 2014